Arix Bioscience, a global healthcare and life science company supporting medical innovation, has announced that has been appointed as non-executive director to the Arix board of directors.
Jonathan Peacock, executive chairman of Arix, commented: “I am very pleased to welcome Art to the board of Arix. He brings extensive experience both as a senior executive in the pharmaceutical industry and in building Pappas Capital as a leading life sciences venture capital firm in the US.
Pappas commented: “Arix is committed to building and supporting the development of young companies developing innovative therapies for important unmet medical needs. Since IPO, Arix has grown significantly having built a diverse and innovative portfolio, a unique group of industry and academic partners, and a talented investment team in the UK and US. Arix offers a compelling proposition to investors looking to access innovation in life sciences, and I look forward to supporting the Company’s continued growth and development.”
Arthur Pappas brings over 30 years of experience as a pharmaceutical and biotechnology industry executive, and venture capital investor in life science companies.
He previously served as chairman and founding CEO of CoLucid Pharmaceuticals, and on the boards of Afferent Pharmaceuticals, Chimerix , Quintiles Transnational, TYRX, Syntonix Pharmaceuticals, LEAD Therapeutics, CardioDx and Embrex. He also served as a board observer for Plexxikon, which was sold to Daiichi Sankyo in 2011.
